Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library

Key Points • APC is a pleiotropic coagulation protease with anticoagulant, anti-inflammatory, and cytoprotective activities.• An APC nonactive site–specific nanobody library is developed to selectively modulate APC for potential therapeutic purpose.

[1]  J. Huntington,et al.  Serpinpc in Persons with Severe Hemophilia (PwH): Updated Results from a Multi-Center, Multi-Part, First-in-Human Study , 2022, Blood.

[2]  C. Esmon,et al.  Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C , 2022, Blood advances.

[3]  C. Esmon,et al.  Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy. , 2022, Blood.

[4]  M. Cohen,et al.  An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice , 2021, Blood advances.

[5]  A. J. Schuhmacher,et al.  Transportation of Single-Domain Antibodies through the Blood–Brain Barrier , 2021, Biomolecules.

[6]  C. Casari,et al.  Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications , 2020, Research and practice in thrombosis and haemostasis.

[7]  E. Di Cera,et al.  Zymogen and activated protein C have similar structural architecture , 2020, The Journal of Biological Chemistry.

[8]  P. Ellinger,et al.  Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia , 2020, Nature Communications.

[9]  J. Oldenburg,et al.  Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers. , 2020, Nucleic acid therapeutics.

[10]  Wei Huang,et al.  Biology, role and therapeutic potential of circulating histones in acute inflammatory disorders , 2018, Journal of cellular and molecular medicine.

[11]  J. Griffin,et al.  Activated protein C, protease activated receptor 1, and neuroprotection. , 2018, Blood.

[12]  José A Fernández,et al.  PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. , 2018, Blood.

[13]  R. M. Pino,et al.  Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis , 2018 .

[14]  J. Huntington,et al.  Design and characterization of an APC-specific serpin for the treatment of hemophilia. , 2017, Blood.

[15]  J. Griffin,et al.  Activated protein C: biased for translation. , 2015, Blood.

[16]  F. Stavenuiter,et al.  Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. , 2014, Blood.

[17]  F. Koch-Nolte,et al.  Nanobodies as modulators of inflammation: potential applications for acute brain injury , 2014, Front. Cell. Neurosci..

[18]  C. Jackson,et al.  Activated protein C: A regulator of human skin epidermal keratinocyte function. , 2014, World journal of biological chemistry.

[19]  J. Griffin,et al.  Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. , 2014, Current pharmaceutical design.

[20]  L. O. Mosnier,et al.  Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. , 2013, Blood.

[21]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[22]  S. Goldman,et al.  An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway , 2013, The Journal of Neuroscience.

[23]  J. Griffin,et al.  Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. , 2012, Blood.

[24]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[25]  C. Esmon.  Protein C anticoagulant system—anti-inflammatory effects , 2011, Seminars in Immunopathology.

[26]  A. Gale,et al.  Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation , 2011, British journal of haematology.

[27]  M. Cohen,et al.  INCREASE IN ACTIVATED PROTEIN C MEDIATES ACUTE TRAUMATIC COAGULOPATHY IN MICE , 2009, Shock.

[28]  Jun Xu,et al.  Extracellular histones are major mediators of death in sepsis , 2009, Nature Medicine.

[29]  C. Esmon,et al.  Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride‐induced septic shock , 2009, Journal of thrombosis and haemostasis : JTH.

[30]  T. Madhusudhan,et al.  An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. , 2009, Chemistry & biology.

[31]  José A Fernández,et al.  Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1 , 2008, The Journal of Neuroscience.

[32]  J. Griffin,et al.  Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions* , 2007, Journal of Biological Chemistry.

[33]  P. Panizzi,et al.  Exosites in the substrate specificity of blood coagulation reactions , 2007, Journal of thrombosis and haemostasis : JTH.

[34]  G. Nuttall.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th ed. , 2007 .

[35]  L. Wyns,et al.  Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Rezaie,et al.  The functional significance of the autolysis loop in protein C and activated protein C , 2005, Thrombosis and Haemostasis.

[37]  A. Lombardi,et al.  Mild bleeding diathesis in a boy with combined severe haemophilia B (C10400→T) and heterozygous factor V Leiden , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[39]  R. Junker,et al.  Symptomatic Onset of Severe Hemophilia A in Childhood is Dependent on the Presence of Prothrombotic Risk Factors , 2001, Thrombosis and Haemostasis.

[40]  J. Griffin,et al.  The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. , 2000, Blood.

[41]  B. Dahlbäck,et al.  Interspecies Loop Grafting in the Protease Domain of Human Protein C Yielding Enhanced Catalytic and Anticoagulant Activity , 1999, Thrombosis and Haemostasis.

[42]  P. Urvil,et al.  Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function. , 1998, European journal of biochemistry.

[43]  Lode Wyns,et al.  Potent enzyme inhibitors derived from dromedary heavy‐chain antibodies , 1998, The EMBO journal.

[44]  Lode Wyns,et al.  Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme , 1996, Nature Structural Biology.

[45]  R. Kaufman,et al.  Moderation of hemophilia A phenotype by the factor V R506Q mutation. , 1996, Blood.

[46]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[47]  J. Oldenburg,et al.  In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. , 2016, Nucleic acid therapeutics.

[48]  J. Griffin,et al.  Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. , 2004, Blood.